BostonGene to Present AI-Powered Platform at 22nd Annual Japanese Society of Medical Oncology Meeting
BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO 2025) from March 6-8, 2025, in Kobe, Japan. The prestigious event brings together global oncology experts to promote collaboration and advance precision oncology. BostonGene’s presence at the meeting will showcase how its innovative AI-powered multiomics platform is revolutionizing cancer biology and improving treatment selection by integrating multi-modal, multi-scale data analysis.
Nathan Fowler, MD, Chief Medical Officer at BostonGene, will deliver a keynote presentation at the symposium, titled “Cutting Edge of Genomic Medicine and Novel Therapy in Hematologic Malignancies.” Dr. Fowler will discuss how BostonGene’s collaborations with leading clinical partners leverage advanced multiomics techniques to identify biomarker predictors of treatment success, shaping the future of drug development. His presentation will highlight the importance of these techniques in optimizing treatment strategies for hematologic cancers.
In addition to Dr. Fowler’s keynote, BostonGene will present several research findings during the meeting, showcasing its groundbreaking work in cancer genomics, immune profiling, and AI-powered treatment strategies.
Symposium and Oral Presentations:
- March 6 | 8:30 AM – 10:00 AM JST | Symposium 3 – Room 4
BostonGene’s first oral presentation will focus on its multiomic clustering approach for cutaneous melanoma patients. This presentation will demonstrate how integrating genomic and transcriptomic data can reveal tumor immune microenvironment patterns that are linked to survival in patients with cutaneous melanoma. The goal is to help clinicians identify survival trends based on immune evasion features of the tumor. - March 8 | 8:30 AM – 9:30 AM JST
The second oral presentation will delve into the sarcomatoid features of clear cell renal cell carcinoma (ccRCC) using RNA sequencing. The presentation will highlight BostonGene’s predictive modeling in the development of targeted therapies for ccRCC, emphasizing its Tumor Portrait™ test. This test identifies unique and targetable clinical features within cancers, improving therapy selection and patient outcomes.
Poster Presentations:
- March 6 | 1:05 PM – 1:50 PM JST
BostonGene will present on improving the reliability of germline variant detection in next-generation sequencing. This study discusses the company’s bioinformatic approach to mitigate false positive germline variant calling, focusing on mappability and allele frequency analysis. - March 7 | 2:05 PM – 2:50 PM JST
A large-scale prospective research study on the clinical utility of RNA- and DNA-based comprehensive genomic profiling in patients with advanced cancers will be presented. This research investigates how BostonGene’s advanced genomic profiling can provide valuable insights into the diagnosis and treatment of advanced malignancies, improving patient outcomes. - March 7 | 2:05 PM – 2:50 PM JST
In another key poster session, BostonGene will showcase its machine learning-enabled automation in flow cytometry. This presentation will explore how a novel machine learning-based cell classification algorithm can reduce turnaround time for analyzing cell populations, improving efficiency in cancer research and diagnostics. - March 8 | 1:05 PM – 1:50 PM JST
BostonGene will also present its work on immune-based treatment of extraskeletal myxoid chondrosarcoma, a rare cancer with limited treatment options. By leveraging next-generation gene profiling, BostonGene’s comprehensive genomic analysis has guided targeted therapy selection for advanced disease.
The meeting will provide valuable opportunities for BostonGene to engage with the oncology community and discuss the role of its cutting-edge AI-powered platform in advancing cancer research and treatment. The presentations will showcase how BostonGene’s platform can decode cancer patients’ molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets, and recommend the most effective treatments.
About BostonGene Corporation:
BostonGene is a biotechnology company founded in 2015, specializing in advanced computational biology and precision medicine. The company is focused on improving patient care and accelerating drug development by using its AI-powered multiomics platform. BostonGene decodes the molecular profiles of cancer patients, analyzing both their immune system and tumor microenvironment. By identifying key disease drivers and novel drug targets, BostonGene provides actionable insights for precision medicine, advancing both research and clinical care in oncology.
With a next-generation CLIA-certified, CAP-accredited laboratory and an indication-specific cancer library, BostonGene delivers clinically validated insights that support oncologists in making the most informed treatment decisions. The company’s platform offers comprehensive, data-driven recommendations that help clinicians select the most effective treatments, advancing personalized care for cancer patients.
